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Abstract
Background: Due to limited therapeutic options, vancomycin-resistant Enterococcus faecium (VREF) is of great
clinical significance. Recently, rising proportions of vancomycin resistance in enterococcal infections have been
reported worldwide. This study aims to describe current epidemiological trends of VREF in German hospitals and to
identify factors that are associated with an increased likelihood of vancomycin resistance in clinical E. faecium
isolates.
Methods: 2012 to 2017 data from routine vancomycin susceptibility testing of 35,906 clinical E. faecium isolates
from 148 hospitals were analysed using data from the German Antimicrobial Resistance Surveillance System.
Descriptive statistical analyses and uni- and multivariable regression analyses were performed to investigate the
impact of variables, such as year of sampling, age and region, on vancomycin resistance in clinical E. faecium
isolates.
Results: From 2014 onwards the proportions of clinical E. faecium isolates exhibiting resistance to vancomycin
increased from 11.2% (95% confidence interval [CI] 9.4–13.3%) to 26.1% (95% CI 23.1–29.4%) in 2017. The rise of
VREF proportions is primarily observed in the southern regions of Germany, whereas northern regions do not show
a major increase. In the Southwest and Southeast, VREF proportions increased from 10.8% (95% CI 6.9–16.5%) and
3.8% (95% CI 3.0–11.5%) in 2014 to 36.7% (95% CI 32.9–40.8%) and 36.8% (95% CI 29.2–44.7%) in 2017, respectively.
VREF proportions were considerably higher in isolates from patients aged 40–59 years compared to younger
patients. Further regression analyses show that in relation to secondary care hospitals, E. faecium samples collected
in specialist care hospitals and prevention and rehabilitation care centres are more likely to be vancomycin-resistant
(odds ratios: 2.4 [95% CI 1.2–4.6] and 2.4 [95% CI 1.9–3.0], respectively). No differences in VREF proportions were
found between female and male patients as well as between different clinical specimens.
Conclusion: The proportion of VREF is increasing in German hospitals, particularly in southern regions in Germany.
Increased efforts in infection control and antibiotic stewardship activities accounting for local resistance patterns are
necessary to combat the spread of VREF in Germany.
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Background
Enterococcus faecium is a Gram-positive, facultative an-
aerobic, catalase-negative bacterium that commonly in-
habits the intestinal tracts of healthy humans [1]. In
addition to its role as a commensal in humans, E. fae-
cium has been described as an emerging pathogen that
causes a significant number of nosocomial infections, in-
cluding infections of the bloodstream, urinary tract, skin
and endocardium [2]. Data from the United States [3]
and Germany [4] show that E. faecium is among the
most frequent causes of healthcare-associated infections
with considerable potential for healthcare-acquired out-
breaks. Evidence indicates that E. faecium strains that
cause nosocomial infections are different from strains that
colonize healthy humans highlighting the role of health-
care centres in the spread of E. faecium infections [5–7].
The clinical relevance of E. faecium is directly linked to
its intrinsically low susceptibility to a broad spectrum of
antimicrobial agents, including low-dose penicillin and
ampicillin, aminoglycosides, sulphonamides and cephalos-
porines [8, 9]. After its first detection in the late 1980’s,
vancomycin resistance in Enterococci (VRE), including E.
faecium, started to emerge in hospitals in the United
States eventually spreading to Europe and worldwide lim-
iting therapeutic options against enterococcal infections
[10]. Due to its clinical significance, the World Health
Organization (WHO) assigned vancomycin-resistant E.
faecium (VREF) as a high priority pathogen on its global
priority list of antibiotic-resistant bacteria [11].
According to 2017 data from the European Antimicro-
bial Resistance Surveillance Network (EARS-Network),
the mean proportion of vancomycin-resistant E. faecium
in blood and cerebrospinal fluid isolates is 14.9% (95% CI
14–16) in participating European countries and 16.5%
(95% CI 15–18) in Germany [12]. Findings from the
German national nosocomial infection surveillance system
(Krankenhaus-Infektions-Surveillance-System, acrony-
mized as “KISS”) show continuously increasing rates of
vancomycin-resistant Enterococci from nosocomial blood-
stream and urinary tract infections acquired in intensive
care units (ICU) between 2007 and 2016 [13].
Despite the data available for Germany, a comprehen-
sive picture of the epidemiological situation of vanco-
mycin-resistant E. faecium in German hospitals is
lacking. In particular, it is not known whether distinct
patient characteristics (e.g. gender, age, site of infection)
or other factors (e.g. hospital care type) are associated
with an increased risk of VREF. Therefore, this study
aims to analyse trends and risk factors of vancomycin re-
sistance of Enterococcus faecium in Germany using data
from the German national Antimicrobial Resistance
Surveillance (ARS) System. Furthermore, the study ana-
lyses trends in the number of infections or colonisations
with VREF diagnosed in German hospitals using publicly
available data from the German hospital payment system
based on fee-for-case on diagnosis related groups.
Methods
Study design and the German antimicrobial resistance
surveillance database
In order to investigate the epidemiology of vancomycin-
resistant E. faecium, a retrospective observational study
was conducted analysing data from the Antimicrobial
Resistance Surveillance (ARS) database from 2012 to
2017. ARS is the national surveillance system for anti-
microbial resistance in Germany established by the
Robert Koch-Institute in 2008 [14]. Voluntarily partici-
pating microbiology laboratories submit results from
routine pathogen identifications and antimicrobial sus-
ceptibility testing. In addition to microbiological results,
participating laboratories provide various pseudonymised
information including clinical specimen material (e. g.
blood, urine and swabs), patient data (age, gender), hos-
pital type (e. g. secondary or tertiary care hospitals) and
geographical location of patient care [15, 16]. As of
2017, more than 50 laboratories contribute to the ARS
database, which includes data from more than 600 out
of a total of 1924 hospitals in Germany. Since ARS par-
ticipation is based on laboratories rather than active
participation of hospitals, a major selection bias towards
certain hospitals (e.g. only those with implemented anti-
biotic stewardship programs) can be excluded. All partici-
pating laboratories possess accreditation for performing
microbiological analyses. Data transmitted to the ARS
database are routinely validated and checked for plausibil-
ity, completeness and consistency. ARS data are used to
generate reference resistance data and feedback reports to
support hospitals in their antibiotic stewardship programs.
ARS resistance data of common pathogens are also avail-
able to the public (https://ars.rki.de/).
Selection of E. faecium isolates
The participation of individual laboratories in ARS can
change over time which can potentially alter the set of
hospitals that provide clinical samples to ARS. In order
to avoid systematic changes in the case mix, only E.
faecium isolates from hospitals with continuous yearly
participation in ARS between 2012 and 2017 were in-
cluded for the main analyses. To avoid biases through
inclusion of multiple E. faecium isolates from one pa-
tient during one disease episode, only the patient’s first
isolate for each quarter of the year was included. How-
ever, since vancomycin-resistant enterococci are known
to persist in the human gut for several months [17], it
cannot be fully excluded that a specific VREF strain has
been counted repeatedly from the same patient. Further-
more, isolates were excluded if they were likely derived
for screening purposes (labelled as screening, anal swabs
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and stool samples). E. faecium isolates without vanco-
mycin susceptibility testing were excluded.
Outcomes and co-variables
The primary outcome is the proportion of vancomycin-
resistant E. faecium isolates among all E. faecium isolates
expressed as percentages (%). An E. faecium isolate was
defined vancomycin resistant if it was tested resistant
against vancomycin in antimicrobial susceptibility testing
according to the applied standard, i. e. standards by
European Committee on Antimicrobial Susceptibility
Testing (EUCAST) or Clinical and Laboratory Standards
Institute (CLSI).
Clinical specimens were grouped by sample site into
urine (urine samples), blood (blood cultures), swabs
(swabs from eye, nose, throat, ear, tongue, urogenital
sites as well as intraoperative swabs and other/unspeci-
fied swabs), wound (swabs from wounds and abscesses)
and other specimens (e. g. punctures, respiratory mate-
rials, unspecified). Patient age was grouped into age
categories (0–19, 20–39, 40–59, 60–79 and, ≥80 years).
Patient gender was classified into female and male. The
geographical origin of the isolates was grouped into five
major regions based on the distribution of hospitals:
Northeast (federal states of Mecklenburg-West Pomer-
ania, Brandenburg, Berlin, Saxony-Anhalt), Northwest
(federal states of Lower Saxony, Bremen, Hamburg,
Schleswig-Holstein), West (North Rhine-Westphalia),
Southwest (Hesse, Rhineland-Palatinate, Saarland,
Baden-Wuerttemberg) and Southeast (Bavaria, Saxony,
Thuringia). Hospital care type was categorised into sec-
ondary care, tertiary care, specialist care, and prevention
and rehabilitation care. All variables were considered as
categorical variables for statistical analyses.
Statistical analyses
All statistical analyses were performed using R version
3.5.1 [18]. Estimates of vancomycin resistance propor-
tions are expressed as percentages with 95% confidence
intervals (95% CI) accounting for clustering on hospital
level using routines in the survey package (version 3.35).
Proportions of vancomycin-resistant E. faecium isolates
between female and male were compared using the
Pearson χ2 test with the Rao-Scott second-order correc-
tion [19] for different age groups. The resulting p-values
were adjusted for multiple testing using a Bonferroni
correction. Risk factors for vancomycin resistance were
analysed using univariable and multivariable logistic re-
gression models accounting for clustering at hospital
level as implemented in the survey package. For univari-
able analyses the following predictors for vancomycin re-
sistance were considered: year of sampling, gender, age
group, specimen (sample site), region and hospital care
type. The multivariable analysis model included all
variables from the univariable analyses. For the multivar-
iable analysis assessing the interaction between region
and year of sampling, the year was treated as a continu-
ous predictor and the interaction between region and
year was included. The same variables as in the model
without interaction were otherwise included.
Sensitivity analyses
It is important to note that some laboratories do not
routinely differentiate Enterococcus isolates into species
level. Systematic bias in VREF proportions therefore
cannot be excluded, such as those introduced by species
differentiation only in selected Enterococcus samples. To
address this issue, time trend analyses of VREF propor-
tions were analysed for E. faecium isolates identified in
laboratories that consistently differentiate more than
95% of all Enterococcus isolates into species level (n =
8492). In addition, sensitivity analyses were performed
that comprised E. faecium isolates (n = 89,450) from all
hospitals including hospitals that did not continuously
participated in ARS between 2012 and 2017.
Data from the hospital payment system based on fee-for-
case on diagnosis related groups
In order to estimate the number of diagnosed
infections or colonisations with VREF between 2013
and 2017, publicly available data from the hospital
payment system based on fee-for-case on diagnosis re-
lated groups (DRG) were analysed. German hospitals
receive a fee-for-case on DRG based on diagnoses ac-
cording to the International Statistical Classification of
Diseases and Related Health Problems Version 10 -
German Modification (ICD-10-GM). According to §21
Hospital Reimbursement Act (Krankenhausentgeltge-
setz) aggregated data must be made publicly available
for scientific use by the Insitute for Reimbursement in
the Hospital (Institut für das Entgeltsystem im
Krankenhaus, InEK) [20]. The dataset contains diagno-
sis data from approximately 1500 out of 1924 German
hospitals. The diagnosis code U80.30 (E. faecium with
resistance to glycopeptide antibiotics, available since
2013) was used to identify cases of E. faecium with re-
sistance to glycopeptide antibiotics. Importantly, a diag-
nosis code for E. faecium with resistance to glycopeptide
antibiotics has been implemented since the beginning of
the DRG system in Germany in 2004 (U.80.3!: E. faecium
with resistance to glycopeptide antibiotics, oxazolidinone,
streptogramine, or high-level-aminoglycoside-resistance).
Therefore, the diagnosis of glycopeptide-resistant E. fae-
cium is well established in German hospitals and a report-
ing bias through introduction of the fee-for-case on DRG
can be excluded.
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Results
Baseline characteristics
In total 35,906 E. faecium isolates from 33,643 patients
and 148 continuously participating hospitals were in-
cluded in the study. The baseline characteristics are out-
lined in Table 1. Samples predominantly originated from
elderly patients (median: 74 years), although isolates
from younger age categories were also available. With a
female / male ratio of 1.16 patients’ gender was nearly
equally distributed in the sample set. The majority of
hospitals and isolates originated from Western and
Southwestern regions in Germany, regions where the
most populated federal states are located, including
North Rhine Westphalia (~ 18m inhabitants) and
Baden-Wuerttemberg (~ 11m). The largest number of E.
faecium isolates was provided by secondary care hospi-
tals (n = 31,182) followed by tertiary care hospitals (n =
3.283), and specialist care hospitals (1109). The most
common clinical sources of E. faecium were urine sam-
ples (n = 16,261), swabs (n = 5687) and wound material
(n = 5550). It is worth mentioning that the ratio of the
total numbers of clinical E. faecium and E. faecalis iso-
lates recorded in ARS did not change between 2012 and
2017 (Additional file 1: Table S1). Compared to other re-
gions in Germany, in the West and Southwest slightly
higher proportions of E. faecium were observed.
Temporal trend and regional analyses
The proportion of E. faecium isolates with resistance
against vancomycin decreased from 15.2% (95% CI 12.0–
19.2%) in 2012 to 11.2% (95% CI 9.4–13.4%) in 2014
(Fig. 1). However, from 2014 onwards, the percentage of
vancomycin-resistant clinical E. faecium isolates con-
tinuously increased reaching 26.1% (95% CI 23.1–29.4%)
in 2017, more than twice that observed 2014. This find-
ing is supported by univariable and multivariable ana-
lyses, which show that isolates collected after 2014 were
increasingly more likely to be tested resistant against
vancomycin than isolates in 2014 (Table 2). A similar
rise of VREF proportions between 2014 and 2017 was
found in sensitivity analyses including E. faecium isolates
that (i) were identified in laboratories that consistently
differentiate more than 95% of all Enterococcus isolates
into species level (Additional file 2: Figure S1A) or (ii)
were provided by all hospitals also including hospitals
that did not continuously participated in ARS between
2012 and 2017 (Additional file 2: Figure S1B). Since
bloodstream infections are of particular clinical interest,
it is noteworthy that in the included hospitals the num-
ber of VREF blood isolates increased from 57 to 120 be-
tween 2014 and 2017 accompanied by a marked rise in
VREF proportions from 11.0% (95% CI 7.2–16.6) in
2014 to 21.1% (95% CI 17.2–25.7%) in 2017.
Table 1 Baseline characteristics of clinical E. faecium isolates
Ntotal 35,906
Year of sampling
2012 (n, %) 4139 11.53
2013 (n, %) 5452 15.18
2014 (n, %) 6326 17.62
2015 (n, %) 6932 19.31
2016 (n, %) 6806 18.96
2017 (n, %) 6251 17.41
Gender of patient
Female (n, %) 17,892 49.83
Male (n, %) 15,370 42.81
NA (n, %) 2644 7.36
Sex ratio (f/m) 1.16
Age of patient
0–19 yrs. (n, %) 527 1.47
20–39 yrs. (n, %) 1183 3.29
40–59 yrs. (n, %) 5547 15.45
60–79 yrs. (n, %) 17,785 49.53
80+ yrs. (n, %) 10,864 30.26
Age (median, IQR) 74.0 63.0–81.0
Specimen (sampling site)
Blood (n, %) 3011 8.39
Urine (n, %) 16,261 45.29
Swab (n, %) 5687 15.84
Wound (n, %) 5550 15.46
Other (n, %) 5280 14.71
NA (n, %) 117 0.33
Region
Southwest (n, %) 11,868 33.05
Southeast (n, %) 395 1.10
West (n, %) 19,508 54.33
Northwest (n, %) 2400 6.68
Northeast (n, %) 1594 4.44
NA (n, %) 141 0.39
Hospital care type
Secondary care (n, %) 31,182 86.84
Tertiary care (n, %) 3283 9.14
Specialist care 1109 3.09
Prevention and rehabilitation care (n, %) 158 0.44
Other (n, %) 33 0.09
NA (n, %) 141 0.39
Hospitals (n) 148
Patients (n) 33,643
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Regional analyses of E. faecium isolates collected between
2012 and 2017 reveal that Germany shows a strong north-
south disparity in VREF proportions. VREF proportions are
noticeably lower in the Northwest (10.8% [95% CI 6.7–
14.8]) and Northeast (10.0% [95% CI 6.7–14.8]) compared
to the Southwest where 20.7% (95% CI 17.1–24.9) of all iso-
lates were tested resistant against vancomycin (Fig. 2A).
Uni- and multivariable regression analyses confirm that E.
faecium isolates from the Northeast and Northwest regions
are less likely to be tested vancomycin resistant than iso-
lates from the Southwest (Table 2). Importantly, temporal
dynamics of VREF proportions differ between the analysed
regions (Fig. 2B). While in the Southwest and Southeast a
pronounced increase of VREF proportions was observed
between 2014 and 2017, the northern regions do not show
a rise of VREF during that same period. In the Southwest
and Southeast, VREF proportions increased from 10.8%
(95% CI 6.9–16.5%) and 3.8% (95% CI 3.0–11.5%) in 2014
to 36.7% (95% CI 32.9–40.8%) and 36.8% (95% CI 29.2–
44.7%) in 2017, respectively. This finding is supported by a
multivariable analysis controlling for interaction between
year and region (Additional file 3: Table S2). It is important
to note that southern regions feature considerably higher
VREF proportions than northern regions only from 2016
onwards.
The absolute number of VREF isolates in the ARS data-
base continuously increased from 631 to 1634 between
2012 and 2017, suggesting that numbers of infections with
vancomycin-resistant E. faecium in German hospitals have
been annually increasing. This trend is supported by our
analysis of publicly available data from the hospital payment
system based on fee-for-case on DRGs [20] that show a
four-fold increase of diagnoses of glycopeptide-resistant E.
faecium infections or colonisations in German hospitals be-
tween 2013 and 2017 (Table 3).
Age and gender
In order to study the influence of the patient age on
vancomycin resistance patterns, VREF proportions were
analysed for different age categories. The results
displayed in Fig. 3 show that E. faecium isolates from
children and adolescents (0–19 years) exhibit markedly
lower vancomycin resistance proportions (7.6% [95% CI
5.4–10.6%]) than young adults (20–39 years) (15.4%
[95% CI 11.1–21.0%]) and older age categories. Multivar-
iable analyses reveal that E. faecium samples from
patient age categories of 0–19 years and 20–39 years are
less likely to be vancomycin-resistant than samples from
patients with an age between 40 and 59 years (Table 2).
Interestingly, the likelihood of vancomycin resistance
tends to decrease in age groups above 60 years, although
the differences are not statistical significant. Further ana-
lyses of all age categories combined do not indicate that
female and male patients differ in VREF proportions (16.5
[95% CI 14.2–19.1%] vs. 16.9 [95% CI 14.1–20.1%]), re-
spectively. However, male young adults (20–39 years) have
higher proportions of vancomycin resistance than their fe-
male counterparts (19.8 vs. 13.6%, adjusted p-value:
0.013), while no differences between both genders were
observed in older age categories (Fig. 3).
Clinical specimen
Since the frequency of drug-resistance pathogens can
differ between infection sites, VREF proportions were
analysed in different clinical specimens, including blood
cultures, urine samples, wound material and swabs. No
major differences in vancomycin resistance proportions
were found between the analysed sampling sites (blood:
14.9% [95% CI 11.3–19.6%], urine: 17.2% [95% CI 14.6–
20.2%], wound: 16.5% [95% CI 13.6–19.9%], swabs:
16.1% [95% CI 13.5–19.0%], other: 15.5% [95% CI 12.2–
19.5%]). Therefore, no associations between clinical spe-
cimen and the likelihood of VREF resistance were found
in uni- and multivariable regression analyses (Table 2).
Hospital care type
To study vancomycin resistance patterns in different
hospital care types, VREF proportions were analysed for
secondary care, tertiary care and specialist care hospitals
as well as prevention and rehabilitation care centres. E.
faecium isolates from secondary care hospitals exhibited
lower proportions of vancomycin resistance (15.2% [95%
CI 12.8–18.0%]) than isolates from tertiary care hospitals
(22.8% [95% CI 10.0–44.1%]) and specialist care hospi-
tals (31.2% [95% CI 16.9–50.4%]) (Fig. 4). Univariable
analyses show that E. faecium samples from tertiary hos-
pital care and specialist hospital care are more likely to
exhibit vancomycin resistance than isolates from second-
ary care (Table 2). However, in multivariable analyses,
no statistical evidence was found that VREF proportions
differ between secondary and tertiary care hospitals (p =
0.191). Interestingly, remarkably high proportions of
VREF were observed in isolates from patients treated in
Fig. 1 Time trend of vancomycin-resistant E. faecium. Time trend of
vancomycin-resistant E. faecium as a proportion (%) of all E. faecium
isolates with corresponding 95% confidence intervals
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prevention and rehabilitation care centres, where more
than one third of all E. faecium isolates are found to be
resistant to vancomycin (36.7% [CI 95% 26.8–47.9%]. In
line with that, the multivariable regression analysis iden-
tified prevention and rehabilitation care centres as an in-
dependent risk factor of increased likelihood of VREF
resistance in relation to secondary care hospitals.
Discussion
By analysing data from the German Antibiotic Resistance
Surveillance system the present study shows that from
2014 onwards the proportions of clinical E. faecium iso-
lates exhibiting resistance to vancomycin increased from
11 to 26% in 2017. Regional analyses reveal that, in par-
ticular, southern regions of Germany have been affected
by a pronounced rise of VREF proportions, whereas
northern regions do not feature substantial increases of
VREF. Middle aged adults (40–59 years) exhibit mark-
edly higher VREF proportions than children and adoles-
cents (0–20 years) and young adults (20–39 years).
While VREF proportions do not differ between female
and male patients in the whole dataset, subgroup
Table 2 Uni- and multivariable analyses of factors associated with vancomycin resistance in clinical E. faecium isolates
univariable analysis multivariable analysis
OR (95% CI) p-value OR (95% CI) p-value
Year of sampling
2012 1.42 (1.12–1.80) 0.004 1.58 (1.16–2.14) 0.004
2013 1.26 (1.01–1.58) 0.044 1.27 (0.99–1.63) 0.061
2014 1 – – 1 – –
2015 1.22 (0.98–1.51) 0.072 1.24 (0.99–1.55) 0.060
2016 1.81 (1.46–2.23) < 0.001 1.80 (1.45–2.25) < 0.001
2017 2.79 (2.26–3.46) < 0.001 2.74 (2.22–3.39) < 0.001
Region
Southwest 1 – – 1 – –
Southeast 0.71 (0.53–0.95) 0.022 0.74 (0.54–1.01) 0.057
West 0.68 (0.46–1.00) 0.051 0.82 (0.55–1.20) 0.303
Northwest 0.46 (0.35–0.61) < 0.001 0.51 (0.36–0.72) < 0.001
Northeast 0.43 (0.27–0.67) < 0.001 0.47 (0.31–0.71) 0.001
Gender
Female 1 – – 1 – –
Male 0.97 (0.90–1.06) 0.533 1.03 (0.94–1.11) 0.554
Age
0–19 years 0.38 (0.26–0.58) < 0.001 0.33 (0.23–0.48) < 0.001
20–39 years 0.85 (0.71–1.01) 0.071 0.84 (0.71–0.99) 0.043
40–59 years 1 – – 1 – –
60–79 years 0.96 (0.82–1.12) 0.626 0.94 (0.83–1.06) 0.324
80+ years 0.86 (0.67–1.10) 0.234 0.83 (0.69–1.01) 0.062
Specimen (sampling site)
Blood 1 – – 1 – –
Urine 1.18 (0.92–1.52) 0.20276 1.22 (0.94–1.48) 0.134
Swab 1.09 (0.78–1.51) 0.62974 0.93 (0.74–1.17) 0.547
Wound 1.12 (0.93–1.36) 0.22761 1.08 (0.90–1.29) 0.426
Other 1.04 (0.88–1.23) 0.65102 1.01 (0.85–1.19) 0.952
Hospital care type
Secondary care 1 – – 1 – –
Tertiary care 1.65 (1.01–2.69) 0.047 1.33 (0.87–2.04) 0.191
Specialist care 2.53 (1.15–5.56) 0.023 2.37 (1.22–4.60) 0.012
Prevention and rehabilitation care 3.23 (2.42–4.33) < 0.001 2.39 (1.91–2.98) < 0.001
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analyses show that E. faecium isolates from young adult
men have higher vancomycin resistance proportions
than their female counterparts.
Rising proportions of vancomycin-resistant E. faecium
have also been observed in many other European coun-
tries between 2014 and 2017 as reported by EARS-Net,
Fig. 2 Vancomycin-resistant E. faecium stratified into geographical region. Vancomycin-resistant E. faecium as a proportion (%) of all E. faecium
isolates with corresponding 95% confidence intervals by German region (2012–2017 data) (a) and time trend by German region (b)
Table 3 Analyses of diagnoses of glycopeptide-resitant E.
faecium in German hospitals






The number of diagnoses of infections or colonisations with glycopeptide-
resistant E. faecium between 2013 and 2017 were analysed using publicly
available data from the hospital payment system based on fee-for-case on
diagnosis related groups. The dataset contains diagnosis data of ~ 1500 out of
a total of 1924 existing (2017) German hospitals. The diagnoses code U80.30!
according ICD-10-GM was used to identify cases of E. faecium with resistance
to glycopeptide antibiotics
Fig. 3 Vancomycin-resistant E. faecium stratified into age and
gender. Vancomycin-resistant E. faecium (VREF) as a proportion (%)
of all E. faecium isolates with corresponding 95% confidence
intervals from male and female patients stratified into age
categories. Proportions of VREF between female and male were
compared using the Pearson χ2 test with the Rao-Scott second-
order correction in different age groups. The resulting p-values were
adjusted for multiple testing using a Bonferroni correction. P-values
≤0.05 are indicated with an “*”. Adjusted p-Values (female vs. male
patients): 0–19 yrs.: p = 0.768, 20–39 yrs.: p = 0.013, 40–59 yrs.: p = 1,
60–79 yrs.: p = 1, 80+ yrs.: p = 1
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including neighbouring countries to Germanys, such as
Denmark, Belgium, Poland and Czech Republic [12].
Only two countries, Ireland and Portugal, in the EU and
European Economic Area (EU/EEA) show a decreasing
trend of VREF proportions between 2014 and 2017
(Portugal 20.1 to 7.2%, Ireland 45.1 to 38.2%). In EARS-
Net AMR data are exclusively collected from invasive
isolates. In line with the findings from EARS-Net our
analyses of VREF proportions in blood isolates also show
increasing trends between 2014 and 2017 in German
hospitals.
Since infections with VREF are associated with worse
clinical outcomes compared to infections with vanco-
mycin-sensitive strains [21–23], rising vancomycin re-
sistance is of great clinical concern in the management
of patients with nosocomial E. faecium infections. As a
matter of fact, a recent population-level study using data
from EARS-Net showed that there were about 16,000
nosocomial infections with vancomycin-resistant entero-
cocci, which were associated with 1065 attributable
deaths in the EU/EEA in the year 2015, nearly twice as
many as 2007 [24]. Current German data show increas-
ing trends of nosocomial infections with vancomycin-re-
sistant Enterococci in German hospitals [13, 25]. These
findings are strongly supported by our analyses of pub-
licly available data from German hospitals, which show a
four-fold increase of diagnoses of infections or colonisa-
tions with glycopeptide-resistant E. faecium between
2013 and 2017 underlining the growing significance of
vancomycin-resistant E. faecium in Germany. It is im-
portant to note that rising numbers of diagnoses of in-
fections or colonisations with glycopeptide-resistant E.
faecium may be partly explained by increased screening
efforts in German hospitals, although no representative
information about the development of VRE(F) screening
habits are available. However, in Germany, the Commission
for Hospital Hygiene and Infection Prevention only recom-
mends a VRE(F) screening for risk populations (e.g. patients
with severe comorbidities and haematological diseases) ra-
ther than a general screening for all hospitalized patients
[26]. Rising numbers of infections with vancomycin-resist-
ant enterococci and/or E. faecium have been also reported
for other countries around the world, including Switzerland
[27], Australia [28] and Canada [29, 30]. Interestingly, our
data show that the ratio of clinical E. faecium and E. faecalis
isolates recorded in ARS is higher in West and South
Germany suggesting a more prominent role of E. faecium
in enterococcal infections in these regions.
Analyses of resistance trends between different geo-
graphical regions in Germany between 2012 and 2017
reveal that VREF proportions significantly vary within
Germany exhibiting a pronounced north-south disparity.
While VREF proportions remained stable in northern re-
gions, a marked increase of VREF proportions was ob-
served in hospitals in the Southwest. From 2016 onwards
VREF proportions in the South were significantly higher
than in the North. VREF strain characterization based on
whole genome sequencing performed at the National Ref-
erence Centre for Enterococci for all bloodstream isolates
between 2015 and 2018 (n = 448) revealed prevalence of
certain strain types associated to specific regions. Whereas
ST117/CT71 was mainly spread throughout Germany and
found in at least nine Federal States, isolates of ST117/
CT469, ST80/CT1065 and ST80/CT1066 were mainly
prevalent in Southwestern Germany ([7] and Jennifer K.
Bender und Guido Werner, unpublished data). Therefore,
the increase in VREF rates in certain regions in Germany
might be associated with a preferred prevalence of certain
strain types.
Increasing proportions of enterococci infections with
vancomycin-resistant strains in Germany are also ob-
served in data from the national Nosocomial infection
surveillance system (KISS). In contrast to our findings,
KISS identified a belt of states with higher proportions
of vancomycin-resistant enterococci infections in the
centre of Germany spanning from west to east [13]. The
different results to our surveillance system might be ex-
plained by different methodological approaches used in
the KISS study, such as only inclusion of bloodstream
and urinary tract infections from ICUs and wound infec-
tions from surgical departments. The reasons for the re-
gional differences observed in our study are largely
unknown. However, a large representative population-
based study analysing German antibiotic prescription
data reported higher outpatient antibiotic prescription of
fluoroquinolones in southwestern regions of Germany
[31]. The extensive use of fluoroquinolones has been
shown to be associated with the emergence of vancomycin-
Fig. 4 Vancomycin-resistant E. faecium stratified into hospital care
type. Vancomycin-resistant E. faecium as a proportion (%) of all E.
faecium isolates with corresponding 95% confidence intervals by
hospital care type
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resistant enterococci in the hospital setting [32]. This find-
ing underlines the importance of the implementing of in-
terventions that improve outpatient antibiotic prescribing
[33]. It is important to note that the analyses of regional re-
sistance patterns are based on the location of the hospital
rather than the residence of the patient. Nevertheless, hos-
pital density in Germany is relatively high and it has been
reported that the majority of patients are treated in hospi-
tals fewer than 60 km from the patients places of residence
[34]. This suggests that the described regional VREF pro-
portions are a true reflection of the acquisition of VREF in
the respective regions, irrespective of whether they were ac-
quired in the hospital or in the community.
Very little is known about factors associated with in-
creased vancomycin resistance in clinical E. faecium iso-
lates in Germany. This study did not find any differences
in VREF proportions between female and male patients.
This finding is also reported in other studies from differ-
ent regions in the world [35–38]. In contrast, a study
analysing data from three New York hospitals found that
isolates from female patients have a higher likelihood of
being vancomycin-resistant than samples from men [39].
However, that particular study analysed infections with
Enterococcus faecalis or Enterococcus faecium. Interest-
ingly, we observed that young male adults (20–39 years)
exhibit markedly higher proportions of VREF than
young female adults (20% vs. 14%), a finding that has
not been described for E. faecium yet.
Since it has been known that different age groups ex-
hibit different microbial susceptibility proportions, VREF
resistance patterns were analyzed for different age cat-
egories. Patients older than 40 years exhibit higher VREF
proportions than children and adolescents (> 15% vs.
7%). Similar age trends have been reported for other
bacterial pathogens, including Staphylococcus aureus,
Escherichia coli, Streptococcus pneumoniae, Pseudo-
monas aeruginosa, Helicobacter pylori and Klebsiella
pneumonia [16, 40–42]. A possible explanation is that
older patients are more likely to be colonised with drug-
resistant pathogens due to more frequent exposure to
antibiotics throughout their lives, thereby promoting the
selection of drug-resistant bacteria as described for en-
terococci [43]. In addition, in comparison to younger pa-
tients elderly patients are likely to have more comorbidities
and are more likely to reside in nursing homes or other
healthcare facilities, both factors that have been shown to
be associated with increased antibiotic resistance [44].
Since nosocomial bloodstream infections are of particu-
lar public health relevance and are often associated with
worse outcomes than other infection types [45–48], VREF
proportions were analysed in clinical blood samples and
other specimen. Blood samples do not show higher VREF
proportions compared with urine samples, wound mater-
ial and swabs. Interestingly, it has been shown that
vancomycin resistance does not further increase the risk
of in-hospital mortality and infection-attributed hospital
stay in bloodstream infections with E. faecium but is asso-
ciated with increased overall hospital costs [49].
This study indicates that VREF proportions are higher
in specialist care hospitals and prevention and rehabilita-
tion care centres, a finding that is possibly explained by
the larger number of patients with comorbidities and
other factors (e. g. age) that are associated with acquiring
resistant bacteria. Specialist care hospitals and preven-
tion and rehabilitation care centres have also been iden-
tified as risk factors for antimicrobial resistance in
Klebsiella pneumoniae in Germany [16].
Strengths and limitations
This study used data from the ARS database which is
the largest and most comprehensive surveillance system
for antimicrobial resistance in Germany [14, 50]. As of
2017, ARS comprised of data from more than 600 par-
ticipating hospitals across all regions in Germany allow-
ing for detailed analyses of epidemiological trends. To
our knowledge, with more than 35.000 clinical isolates
of E. faecium collected from more than 33,000 patients
our study represents the most comprehensive analysis of
recent trends of VREF in German hospitals. However, it
is important to consider the limitations of this study.
First, participation in ARS is voluntary, and thus, partici-
pating laboratories and hospitals are not equally distrib-
uted resulting in a clustering in certain regions. In
particular, northern regions are under-represented in the
sample set, while the Western region is overrepresented.
Therefore, statistical analyses were used that accounted
for clustering effects. Second, since information on
underlying diagnoses is not collected in ARS, it is not
possible to differentiate between colonisation and infec-
tion. To address this issue, isolates were excluded if they
were likely collected for screening purposes. Third, al-
though the analyses were restricted to hospitals that
continuously participated in ARS between 2012 and
2017, it cannot ruled out that changes in hospital struc-
tures and case mix might have biased the longitudinal
observations results. To account for these limitations the
key finding of increasing VREF proportion and different
regional patterns were confirmed by sensitivity analyses
and regression analyses assessing the interaction be-
tween region and year which underlines the robustness
of the results presented in this study.
Conclusion
Proportions of vancomycin resistance in clinical E.
faecium isolates from German hospitals are increasing
underlining the growing significance of E. faecium infec-
tions for public health. VREF proportions differ consid-
erable among German regions with a particular focus of
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high vancomycin resistance in Southwest and Southeast
Germany. Continued surveillance and implementation of
effective infection prevention and control measures ac-
counting for local resistance differences are needed to
reduce the spread of vancomycin-resistant E. faecium in
German hospitals.
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